IL6R and COVID-19: In the COVID-19 scenario with mAb concentrations at 1% of those in plasma, IL-6 bioactivity was minimally inhibited even with repeated daily injections of anti-IL-6 or anti-IL-6R mAb, either alone or in combination (Supplementary Figure 4).